Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax

Article Medicine, General & Internal

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Pau Montesinos et al.

Summary: This study demonstrated that the combination therapy of oral ivosidenib and azacitidine showed better event-free survival and longer overall survival in patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Oncology

Acute myeloid leukemia: current progress and future directions

Hagop Kantarjian et al.

Summary: Advancements in understanding and therapy of AML have been rapid, with targeted therapies such as venetoclax and FLT3 inhibitors being approved for various indications. Expertise is crucial in managing the complexity of AML treatment, tailored to the specific subentities for optimal outcomes.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Hematology

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Maximilian Stahl et al.

Summary: Combination therapy of venetoclax is effective in many patients with relapsed or refractory AML, with azacitidine+venetoclax showing higher response rates compared to low-dose cytarabine+venetoclax. Clinical and molecular characteristics of patients may predict treatment outcomes in this population.

BLOOD ADVANCES (2021)

Add to Collection

Review Hematology

Harnessing the benefits of available targeted therapies in acute myeloid leukaemia

Hagop Kantarjian et al.

Summary: Since 2017, the US FDA has approved nine agents for acute myeloid leukaemia, including Bcl-2 inhibitors, FLT3 inhibitors, and IDH inhibitors. Some of the approved agents are used as single-agent therapies or specific combinations for narrow indications, offering limited treatment value.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Feng Wang et al.

Summary: The authors found that stemness features are the major drivers of primary resistance to IDH inhibitors, while high-risk mutations are the main drivers of acquired resistance. Targeting stemness and certain high-risk co-occurring mutations may help overcome resistance to IDH inhibitors in AML.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Hematology